Abbvie Inc will Acquire ImmunoGen Inc M&A Call Transcript
Good day, and thank you for standing by. Welcome to the AbbVie Investor and Analyst Conference Call. (Operator Instructions) Today's call is also being recorded. If you have any objections, you may disconnect at this time. I would now like to introduce Ms. Liz Shea, Senior Vice President of Investor Relations. Thank you. You may begin.
Good morning, and thank you for joining us for this special conference call to discuss AbbVie's acquisition of ImmunoGen, which we announced earlier today. Joining me on the call today are Rick Gonzalez, Chairman of the Board and Chief Executive Officer; Rob Michael, President and Chief Operating Officer; and Scott Reents, Executive Vice President and Chief Financial Officer. Joining us for the Q&A portion of the call are Jeff Stewart, Executive Vice President, Chief Commercial Officer; Nicholas Donoghoe, Executive Vice President, Chief Business and Strategy Officer; and Roopal Thakkar, Senior Vice President, Development and Regulatory Affairs and Chief Medical Officer.
Today's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |